Division of Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.
Am J Cardiol. 2013 Aug 15;112(4):574-9. doi: 10.1016/j.amjcard.2013.04.023. Epub 2013 May 16.
Brain natriuretic peptide (BNP) is a marker of systolic and diastolic dysfunction and a strong predictor of mortality in heart failure patients. The present study aimed to assess the relationship of BNP with aortic stenosis (AS) severity and prognosis. The cohort comprised 289 high-risk patients with severe AS who were referred for transcatheter aortic valve implantation. Patients were divided into tertiles based on BNP level: I (n = 96); II (n = 95), and III (n = 98). Group III patients were more symptomatic, had higher Society of Thoracic Surgeons and EuroSCORE scores, and had a greater prevalence of renal failure, atrial fibrillation, and previous myocardial infarction; lower ejection fraction and cardiac output; and higher pulmonary pressure and left ventricular end diastolic pressure. The degree of AS did not differ among the 3 groups. Stepwise forward multiple regression analysis identifies ejection fraction and pulmonary artery systolic pressure as independent correlates with plasma BNP. Mortality rates during a median follow-up of 319 days (range 110 to 655) were significantly lower in Group I compared with Groups II and III, p <0.001. After multivariable adjustment, the strongest correlates for mortality were renal failure (hazard ratio 1.44, p = 0.05) and medical/balloon aortic valvuloplasty (HR 2.2, p <0.001). Mean BNP decreased immediately after balloon aortic valvuloplasty from 1,595 ± 1,229 to 1,252 ± 1,076, p = 0.001 yet increased to 1,609 ± 1,264, p = 0.9 at 1 to 12 months. After surgical aortic valve replacement, there was a nonsignificant, immediate decrease in BNP level from 928 ± 1,221 to 896 ± 1,217, p = 0.77, continuing up to 12 months 533 ± 213, p = 0.08. After transcatheter aortic valve implantation, there was no significant decrease in BNP immediately after the procedure; however, at 1-year follow-up, the mean BNP level decreased significantly from 568 ± 582 to 301 ± 266 pg/dl, p = 0.03. In conclusion, a high BNP level in high-risk patients with severe AS is not an independent marker for higher mortality. BNP level does not appear to be significantly associated with the degree of AS severity but does reflect heart failure status.
脑钠肽(BNP)是收缩和舒张功能障碍的标志物,也是心力衰竭患者死亡的强预测因子。本研究旨在评估 BNP 与主动脉瓣狭窄(AS)严重程度和预后的关系。该队列包括 289 名高危重度 AS 患者,他们被转诊接受经导管主动脉瓣植入术。根据 BNP 水平将患者分为三组:I 组(n = 96);II 组(n = 95)和 III 组(n = 98)。III 组患者症状更明显,STS 和 EuroSCORE 评分更高,肾衰竭、心房颤动和既往心肌梗死的发生率更高;射血分数和心输出量较低;肺动脉压和左心室舒张末期压较高。三组间 AS 程度无差异。逐步向前多元回归分析确定射血分数和肺动脉收缩压是与血浆 BNP 独立相关的因素。在中位数为 319 天(范围 110 至 655)的中位随访期间,I 组的死亡率明显低于 II 组和 III 组,p <0.001。多变量调整后,死亡率的最强相关因素是肾衰竭(危险比 1.44,p = 0.05)和内科/球囊主动脉瓣成形术(HR 2.2,p <0.001)。球囊主动脉瓣成形术后,BNP 立即从 1595 ± 1229 pg/ml 降至 1252 ± 1076 pg/ml,p = 0.001,但在 1 至 12 个月时增加至 1609 ± 1264 pg/ml,p = 0.9。主动脉瓣置换术后,BNP 水平立即出现无显著性下降,从 928 ± 1221 pg/ml 降至 896 ± 1217 pg/ml,p = 0.77,直至 12 个月时为 533 ± 213 pg/ml,p = 0.08。经导管主动脉瓣植入术后,术后即刻 BNP 无显著下降;然而,在 1 年随访时,平均 BNP 水平从 568 ± 582 pg/ml 显著下降至 301 ± 266 pg/ml,p = 0.03。总之,高危重度 AS 患者的高 BNP 水平并不是死亡率较高的独立标志物。BNP 水平似乎与 AS 严重程度无显著相关性,但确实反映了心力衰竭状态。